Research Library

The authors examine a proposal for new human embryo and embryoid guidelines, writing that before conducting any research beyond day 14, scientists must develop clear, thoughtful and culturally sensitive guidelines that include limitations and oversight procedures to ensure that science responds to societal needs and values.

The authors assess U.S. health care system and offer a plan for achieving universal health care. The Lancet: http://bit.ly/2lSaqX6

By Morgan N. Fredell, Hagop M. Kantarjian, Ya-Chen Shih, Vivian Ho and Binata Mukherjee Current U.S. health care spending includes many areas of wasted expenditures. In this study, published in Cancer, the authors explore plans to optimize U.S. health care to provide greater benefits to patients: https://bit.ly/2TmeoDg

Nonresident fellow Valentine Moghadam argues that women’s legal status, social positions, and collective action prior to the Arab Spring helped shape the nature of the 2011 mass protests as well as the political and social outcomes of individual countries.

Using the work of the women’s caucus in Iran’s Sixth Parliament as a case study, the authors examine women’s struggles to obtain a voice and influence within an authoritarian polity and a male-dominated political body.

What has the Arab Spring meant for women’s rights in the region? Three years after the mass social protests of January and February 2011, when and where can we expect the promises of democracy and equality, and the revolutionary spirit of unity and purpose, to be realized? This article takes stock of significant events and possible future directions, with a focus on prospects for a women-friendly democratization.

Every patient with cancer or another life-threatening disease wants the most effective treatment, but drug prices have become staggering. What determines the escalating prices of cancer drugs?

For both generic and patented cancer drugs, the free-market economy has not worked well. Solutions are needed to maintain reasonable drug prices that allow for corporate profits and are affordable to patients and to the U.S. health care system.

In a genuine effort to protect patients from adverse events, regulatory burdens and research rigidity in clinical trials have increased to a point at which such protection is outweighing the benefits, and actually harming patients who are unable to be involved in clinical trials.

Allowing the producer-dominated market to set drug prices has spiraled the cost of cancer drugs out of control. Drug pricing can be reduced while preserving the profit-making incentive, by linking price to a true measure of quality: preservation and meaningful prolongation of life.